SCHEMBL1016848

SCHEMBL1016848

CCc1cnco1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102938 0.74
SCHEMBL5266610 0.74
SCHEMBL2566008 0.74
SCHEMBL13949575 0.73
SCHEMBL20418887 0.70
SCHEMBL18381917 0.70
SCHEMBL20414624 0.69
SCHEMBL14268249 0.69 ACACB (0.38)
SCHEMBL16254195 0.69
SCHEMBL18074348 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
EP-3638675-B1 DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS BAYER AG (DE) 2024-04-17 EP disclosed
US-11912738-B2 Neuroactive steroids and their methods of use SAGE THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
WO-2024026479-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
WO-2024026486-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-11873290-B2 2024-01-16 US disclosed
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders Technische Universität Darmstadt (DE) 2023-12-05 US disclosed
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders Technische Universität Darmstadt (DE) 2023-12-05 US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20060183770-A1 Sulfonamide derivative having isoxazole ring SHIONOGI & CO., LTD. (JP) 2006-08-17 US disclosed
WO-2006073361-A1 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2006-07-13 WO disclosed
EP-1650199-A1 SULFONAMIDE DERIVATIVE HAVING ISOXAZOLE RING SHIONOGI & CO., LTD. (JP) 2006-04-26 EP disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 US disclosed
EP-0097720-B1 PROCESS FOR PREPARING SILVER HALIDE EMULSION KONICA CORPORATION (JP) 1986-11-26 EP disclosed
EP-0097720-A1 PROCESS FOR PREPARING SILVER HALIDE EMULSION KONICA CORPORATION (JP) 1984-01-11 EP disclosed
US-4362800-A CYANINE DYES FUJI PHOTO FILM CO., LTD. (JP) 1982-12-07 US disclosed
US-4268620-A Method of processing of light-sensitive silver halide photographic material KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1981-05-19 US disclosed